Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CytoDyn Inc CYDY

Healthcare Biotechnology
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as Metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.


OTCQB:CYDY - Post by User

CytoDyn Inc > .
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1156)
•••
Comment by Pandoraon Mar 21, 2024 12:53am
60 Views
Post# 35944260

RE:.

RE:.
CYDY has a new patent that is virtually approved --  that is, it has been given a Notice of Allowance by the USPTO which means they have to pay a fee and then wait for the approval of a new patent number to be posted.
I would post this on the Yahoo board but for whatever reason I cannot access the board.

17/148,281 | 230042.431:

METHOD OF TREATING METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC) BY ADMINISTERING AN ANTIBODY AGAINST C-C CHEMOKINE RECEPTOR TYPE 5 (CCR5) ANTIBODY


Showing 5 of 53 entries
 
 
/ /
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities